IQVIA (NYSE:IQV) Price Target Cut to $210.00 by Analysts at Citigroup

IQVIA (NYSE:IQV) had its target price cut by Citigroup from $225.00 to $210.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has a “neutral” rating on the medical research company’s stock. Citigroup’s price target suggests a potential upside of 14.37% from the company’s current price.

IQV has been the subject of a number of other research reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a report on Monday, February 10th. JPMorgan Chase & Co. reduced their price target on IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. Leerink Partners reiterated an “outperform” rating and set a $248.00 price target (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Finally, Barclays dropped their price target on IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd. Five investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Price Performance

IQV stock traded down $1.24 during trading on Tuesday, hitting $183.61. 751,335 shares of the stock traded hands, compared to its average volume of 1,201,559. The stock has a market cap of $32.33 billion, a price-to-earnings ratio of 24.49, a P/E/G ratio of 1.99 and a beta of 1.48. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA has a one year low of $179.81 and a one year high of $261.73. The company has a 50 day simple moving average of $198.84 and a 200 day simple moving average of $214.25.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities analysts expect that IQVIA will post 10.84 EPS for the current fiscal year.

Institutional Investors Weigh In On IQVIA

Several large investors have recently modified their holdings of the company. Siemens Fonds Invest GmbH grew its holdings in IQVIA by 973.2% in the fourth quarter. Siemens Fonds Invest GmbH now owns 21,345 shares of the medical research company’s stock worth $4,195,000 after purchasing an additional 19,356 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in IQVIA during the 4th quarter worth approximately $25,152,000. Forum Financial Management LP boosted its holdings in IQVIA by 53.2% in the fourth quarter. Forum Financial Management LP now owns 2,067 shares of the medical research company’s stock worth $406,000 after acquiring an additional 718 shares in the last quarter. Toronto Dominion Bank increased its holdings in shares of IQVIA by 2.2% during the fourth quarter. Toronto Dominion Bank now owns 61,774 shares of the medical research company’s stock valued at $12,139,000 after acquiring an additional 1,358 shares in the last quarter. Finally, GF Fund Management CO. LTD. acquired a new position in shares of IQVIA during the fourth quarter worth approximately $841,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.